Drug delivery system for accelerated subcutaneous absorption

• US 20050287134A1
• Filed: 06/25/2004
• Published: 12/29/2005
• Est. Priority Date: 06/25/2004
• Status: Active Grant

• Current Assignee: Jeffrey A. Klein
• Original Assignee: Jeffrey A. Klein
• Inventors: Klein, Jeffrey A.
• Granted Patent: US 7,572,613 B2
• Time in Patent Office: Days
• US Class Current: 424/94.61
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/166 having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 37/00 Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04

Abstract

A method for accelerating subcutaneous absorption of a fluid or drug into the systemic circulation of a specific targeted tissue. A first drug operative to produce local capillary vasodilatation and/or increase the rate of bulk flow of solution through the interstitial space is mixed with a fluid. The fluid may contain a crystalloid solution or a dilute solution of a pharmacologic drug required for a routine or emergency therapeutic treatment for a patient. The first drug is substantially non-toxic to the patient. The fluid mixed with the first drug is then delivered subcutaneously or into deeper tissues of the patient, by use of a hyperdermic needle or infiltration cannula. As the capillaries are dilated, the fluid is efficiently absorbed and circulated systemically.

Claims

1. A drug delivery method, comprising:

a) dissolving a first drug at a substantially non-toxic concentration with a fluid solvent, wherein the first drug is operative to produce local capillary vasodilatation or to produce increased bulk flow of fluid by depolymerization of hyaluronic acid; and

b) subcutaneously or intramuscularly applying the fluid containing the first drug to a patient.

2. The method of claim 1, wherein the first drug includes methyl-nicotinamide, methyl-nicotinate or hyaluronidase.

3. The treatment of claim 1, wherein fluid includes physiologic saline.

4. The treatment of claim 1, wherein the fluid includes a dilute solution of local anesthetic.

5. The treatment of claim 1, wherein the fluid includes a dilute solution of lidocaine.

6. The treatment of claim 1, wherein step (b) includes applying the fluid containing the first drug by subcutaneous infiltration.

7. The method of claim 6, wherein step (b) includes:

b1) inserting an infiltration cannula under skin of the patient; and

b2) infiltrating the fluid containing the first drug into subcutaneous tissue or muscle of the patient through the infiltration cannula.

8. The method of claim 7, wherein step (b1) includes inserting a plastic infiltrator under the skin of the patient.

9. The method of claim 1, further comprising the step of:

c) applying a solution of a vasoconstrictive drug operative to cause vasoconstriction of cutaneous blood vessels of the patient.

10. The method of claim 9, wherein the vasoconstrictive drug includes a solution of epinephrine.

11. The method of claim 1, wherein the fluid contains a second drug for treating a subcutaneous tissue of the patient

12. A method of increasing absorption rate of a therapeutic drug, comprising:

applying a first solution in a first level under skin of a patient, wherein the first solution contains a therapeutic drug for treating subcutaneous tissue of the patient; and

applying a second solution in a second level under the skin of the patient, wherein the second solution contains a vasoconstrictive drug;

wherein

the second level is deeper than the first level to serve as a buffer for preventing or delaying absorption of the therapeutic drug into deep vascular tissue.

13. The method of claim 12, wherein the first solution further contains a vasodilation drug.

14. The method of claim 12, wherein the vasoconstrictive drug includes epinephrine.

15. The method of claim 12, wherein the first level includes a deep plane of the subcutaneous tissue, and the second level includes a superficial plane immediately below dermis of the patient.

16. A method of increasing absorption rate of a therapeutic drug, comprising:

applying a first solution in a first level under the skin of a patient, wherein the first solution contains a therapeutic drug for treating the skin of the patient; and

applying a second solution in a second level under the skin of the patient, wherein the second solution contains a vasoconstrictive drug only;

wherein

the first level is deeper than the second level to serve as a buffer for preventing or delaying absorption of the therapeutic drug into superficial region of the skin.

17. The method of claim 16, wherein the first solution further contains a vasodilation drug.

18. The method of claim 17, wherein the vasoconstrictive drug comprises epinephrine.